Nov 1 (Reuters) - The U.S. Food and Drug Administration
on Friday warned patients and health care professionals not to
use compounded drugs, including versions of popular weight-loss
treatments, made by California-based Fullerton Wellness.
Fullerton Wellness is a facility that makes compounded
versions of Novo Nordisk's semaglutide and Eli
Lilly's ( LLY ) tirzepatide injections, among others.